Please use this identifier to cite or link to this item: http://scholarbank.nus.edu.sg/handle/10635/130575
Title: Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: A randomized trial
Authors: Chan, H.L.Y.
Heathcote, E.J.
Marcellin, P.
Lai, C.-L.
Cho, M.
Moon, Y.M.
Chao, Y.-C.
Myers, R.P.
Minuk, G.Y.
Jeffers, L.
Sievert, W.
Bzowej, N.
Harb, G.
Kaiser, R.
Qiao, X.-J.
Brown, N.A.
Crawford, D.
Lim, S.-G. 
Chutaputti, A.
Poynard, T.
Issue Date: 4-Dec-2007
Citation: Chan, H.L.Y., Heathcote, E.J., Marcellin, P., Lai, C.-L., Cho, M., Moon, Y.M., Chao, Y.-C., Myers, R.P., Minuk, G.Y., Jeffers, L., Sievert, W., Bzowej, N., Harb, G., Kaiser, R., Qiao, X.-J., Brown, N.A., Crawford, D., Lim, S.-G., Chutaputti, A., Poynard, T. (2007-12-04). Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: A randomized trial. Annals of Internal Medicine 147 (11) : 745-754. ScholarBank@NUS Repository.
Abstract: Background: The efficacy of nucleoside and nucleotide analogues for hepatitis B has been linked to the magnitude and durability of hepatitis B virus (HBV) suppression. Objective: To compare the antiviral efficacy of telbivudine and adefovir dipivoxil, and the effects of switching from adefovir to telbivudine, in hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B. Design: Randomized, controlled, open-label trial. Setting: 16 outpatient clinics. Patients: 135 treatment-naive, HBeAg-positive adults with chronic hepatitis B. Intervention: Patients were randomly assigned in a 1:1:1 ratio to 52 weeks of telbivudine (group A) or adefovir (group B), or 24 weeks of adefovir and then telbivudine for the remaining 28 weeks (group C). One hundred thirty-one patients completed 52 weeks of treatment. Measurements: The primary efficacy comparison was serum HBV DNA reduction at week 24, with a secondary comparison at week 52. Results: At week 24, mean HBV DNA reduction was greater in group A than in pooled groups B and C (-6.30 vs. -4.97 log10 copies/mL; difference, -1.33 log10 copies/mL [95% CI, -1.99 to -0.66 log10 copies/mL]; P < 0.001), and more patients in group A were polymerase chain reaction-negative (39% vs. 12%; odds ratio, 4.46 [CI, 1.86 to 10.72]; P < 0.001). At week 52, the mean residual HBV DNA level was lower in group A and group C than in group B (3.01 log10 copies/mL [group A] and 3.02 log10 copies/mL [group C] vs. 4.00 log10 copies/mL [group B]; difference, -0.99 log10 copies/mL [CI, -1.67 to -0.32 log10 copies/mL] and -0.98 log10 copies/mL [CI, -1.64 to -0.32 log10 copies/mL]; P = 0.004). Adverse events were similar across groups; the most common were upper respiratory symptoms, headache, back pain, and diarrhea. Limitations: The trial was open-label and was not of sufficient size or duration to compare clinical outcomes and long-term efficacy. Conclusion: Telbivudine demonstrated greater and more consistent HBV DNA suppression than adefovir after 24 weeks of treatment. After 52 weeks, HBV DNA suppression was greater in patients who had received continuous telbivudine or were switched to telbivudine after 24 weeks than in those who received continuous adefovir. © 2007 American College of Physicians.
Source Title: Annals of Internal Medicine
URI: http://scholarbank.nus.edu.sg/handle/10635/130575
ISSN: 00034819
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Page view(s)

10
checked on Nov 2, 2018

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.